生命科学资讯

Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says

New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill

Eikon sets $274M goal for upcoming stock market debut

Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M

Oral Rogaine maker Veradermics looks to raise $181M from IPO

FDA asks court to pause Louisiana's abortion pill fight

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

Lonza still intends to sell its capsules and health ingredients business

Lonza still intends to sell its capsules and health ingredients business - Endpoints News

Teva CEO says it has successfully transitioned into a biopharma company

Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

Halozyme buys a biotech startup; Cytokinetics launches heart drug

Regenxbio gene therapy trials suspended by FDA over safety worries

A Glimpse of Thermo Fisher Scientific's Earnings Potential - Benzinga

A GPCR-G protein-β-arrestin megacomplex enabled by a versatile allosteric modulator

Field-effect-informed urine liquid biopsy for bladder cancer

AAVLINK: A potent DNA-recombination method for large cargo delivery in gene therapy

An uORF-encoded mobile peptide sparks systemic stomatal immunity

A triple-node heart-brain neuroimmune loop underlying myocardial infarction

Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss